
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of November, 2024

Commission File No. 001-39621

OPTHEA LIMITED
(Translation of registrant's name into English)

Level 4
650 Chapel Street
South Yarra, Victoria, 3141
Australia
(Address of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F

EXHIBIT INDEX

Exhibit	Description
99.1	Press Release - Opthea's Wet AMD Program Featured at Ophthalmology Events

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

OPTHEA LIMITED

(Registrant)

By: /s/ Frederic Guerard

Name: Frederic Guerard

Title: Chief Executive Officer

Date: 11/12/2024



ASX, Nasdaq and Media Release

November 12, 2024

Opthea's Wet AMD Program Featured at Ophthalmology Events

17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024

Ophthalmology Innovation Summit XIV, November 23, 2024

Melbourne, Australia, and Princeton, NJ, US, November 12, 2024 -- Opthea Limited (ASX/NASDAQ: OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Opthea and sozinibercept will be highlighted during two upcoming Ophthalmology conferences.

Conference details are as follows:

The 17th Congress of the Asia-Pacific Vitreo-Retina Society (APVRS)

Session: Rapid Fire 4 – Retina (Medical & Surgical)

Timing: Friday, November 22, 2024, 3:15 – 3:20 PM Singapore time (GMT+8)

Presentation: Intravitreal Sozinibercept (anti-VEGF-C/D 'trap') Combined with Ranibizumab for the Treatment of Polypoidal Choroidal Vasculopathy: A Predefined Phase 2b Subgroup Analysis

Presenter: Gregg T. Kokame, MD, MMM, FASRS

Abstract: <https://2024.apvrs.org/abstract/?code=200963>

Gregg T. Kokame, MD, MMM, FASRS, will present data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured at 24 weeks. Data from this subgroup show that patients treated with a combination of sozinibercept and ranibizumab experienced significantly better visual and anatomic outcomes compared to ranibizumab alone.

APVRS, themed *Transforming Retinal Disease Management with Technology*, gathers a distinguished international faculty of top specialists in vitreo-retina to share their expertise and experience. The scientific program will focus on exciting areas such as novel surgical innovations and therapies, and latest advances in imaging and research.

Ophthalmology Innovation Summit XIV (OIS)

Session: Retina Innovation Showcase

Timing : Saturday, November 23, 2024, 11:15 AM – 12:50 PM PT

Presenter: Frederic Guerard, PharmD, CEO, Opthea

Agenda: <https://ois.net/ois-xiv-agenda/>

The Ophthalmology Innovation Summit connects clinical, corporate, and capital leaders to drive the ophthalmic market forward. It showcases groundbreaking advancements and clinical insights in both anterior and posterior ophthalmology segments and offers the opportunity to learn, network and collaborate.



About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, [NCT04757636](#), and ShORe, [NCT04757610](#)) for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at www.opthea.com and follow us on [X](#) and [LinkedIn](#).

Authorized for release to ASX by Frederic Guerard, PharmD, CEO

Investor Inquiries

PJ Kelleher
LifeSci Advisors LLC
Email: pkelleher@lifesciadvisors.com
Phone: [617-430 7579](tel:617-430-7579)

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399
Email: info@opthea.com
Web: www.opthea.com

Media Inquiries

Silvana Guerci-Lena
NorthStream Global Partners
silvana@nsgpllc.com

Source: Opthea Limited
